Compare ASTRAZENECA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 106.9 33.8 316.4% View Chart
P/BV x 31.2 3.5 897.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
CIPLA
Mar-19
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,278678 188.5%   
Low Rs883484 182.4%   
Sales per share (Unadj.) Rs228.4198.2 115.2%  
Earnings per share (Unadj.) Rs10.418.5 56.0%  
Cash flow per share (Unadj.) Rs16.335.0 46.5%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs98.8186.3 53.0%  
Shares outstanding (eoy) m25.00805.70 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.9 161.4%   
Avg P/E ratio x104.231.4 332.4%  
P/CF ratio (eoy) x66.416.6 400.1%  
Price / Book Value ratio x10.93.1 350.8%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m27,008468,031 5.8%   
No. of employees `0001.422.6 6.0%   
Total wages/salary Rs m1,53528,565 5.4%   
Avg. sales/employee Rs Th4,210.97,053.1 59.7%   
Avg. wages/employee Rs Th1,132.21,261.5 89.8%   
Avg. net profit/employee Rs Th191.1659.1 29.0%   
INCOME DATA
Net Sales Rs m5,710159,710 3.6%  
Other income Rs m1234,766 2.6%   
Total revenues Rs m5,833164,475 3.5%   
Gross profit Rs m46330,973 1.5%  
Depreciation Rs m14713,263 1.1%   
Interest Rs m01,684 0.0%   
Profit before tax Rs m43820,791 2.1%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1795,695 3.1%   
Profit after tax Rs m25914,924 1.7%  
Gross profit margin %8.119.4 41.8%  
Effective tax rate %40.827.4 149.1%   
Net profit margin %4.59.3 48.6%  
BALANCE SHEET DATA
Current assets Rs m3,209124,266 2.6%   
Current liabilities Rs m2,07037,715 5.5%   
Net working cap to sales %20.054.2 36.8%  
Current ratio x1.63.3 47.1%  
Inventory Days Days7291 79.8%  
Debtors Days Days3595 36.8%  
Net fixed assets Rs m790105,190 0.8%   
Share capital Rs m501,611 3.1%   
"Free" reserves Rs m2,419148,511 1.6%   
Net worth Rs m2,469150,123 1.6%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m4,605239,633 1.9%  
Interest coverage xNM13.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.7 186.0%   
Return on assets %5.66.9 81.2%  
Return on equity %10.59.9 105.5%  
Return on capital %17.711.8 149.8%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30057,410 0.5%   
Fx outflow Rs m2,01519,041 10.6%   
Net fx Rs m-1,71538,368 -4.5%   
CASH FLOW
From Operations Rs m8816,911 0.5%  
From Investments Rs m-94-16,687 0.6%  
From Financial Activity Rs mNA-3,487 0.0%  
Net Cashflow Rs m-6-3,451 0.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 750 Points Higher; Banking Stocks Rally(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.4% while the Hang Seng is up 3.1%.

Related Views on News

CIPLA at 52 Week High; BSE 500 Index Up 2.0% (Market Updates)

Jun 1, 2020 | Updated on Jun 1, 2020

CIPLA share price has hit a 52-week high. It is presently trading at Rs 652. BSE 500 Index is up by 1.9% at 12,650. Within the BSE 500, CIPLA (up 0.4%) and IDBI BANK (up 18.0%) are among the top gainers, while top losers are VODAFONE IDEA and LA OPALA RG.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 1, 2020 09:39 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS